Cargando…

Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors

The purpose of this narrative review was to provide an overview that allows readers to improve their understanding of hemophilia A, which is considered a genetic disease with a high impact on the quality of life of people who suffer from it is considered one of the diseases with the highest cost for...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarmiento Doncel, Samuel, Díaz Mosquera, Gina Alejandra, Cortes, Javier Mauricio, Agudelo Rico, Carol, Meza Cadavid, Francisco Javier, Peláez, Ronald Guillermo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944491/
https://www.ncbi.nlm.nih.gov/pubmed/36810557
http://dx.doi.org/10.3390/hematolrep15010014
_version_ 1784891927103012864
author Sarmiento Doncel, Samuel
Díaz Mosquera, Gina Alejandra
Cortes, Javier Mauricio
Agudelo Rico, Carol
Meza Cadavid, Francisco Javier
Peláez, Ronald Guillermo
author_facet Sarmiento Doncel, Samuel
Díaz Mosquera, Gina Alejandra
Cortes, Javier Mauricio
Agudelo Rico, Carol
Meza Cadavid, Francisco Javier
Peláez, Ronald Guillermo
author_sort Sarmiento Doncel, Samuel
collection PubMed
description The purpose of this narrative review was to provide an overview that allows readers to improve their understanding of hemophilia A, which is considered a genetic disease with a high impact on the quality of life of people who suffer from it is considered one of the diseases with the highest cost for health systems (In Colombia it is part of the five diseases with the greatest economic impact). After this exhaustive review, we can see that the treatment of hemophilia is on the way to precision medicine, which involves genetic variables specific to each race and ethnicity, pharmacokinetics (PK), as well as environmental factors and lifestyle. Knowing the impact of each of these variables and their relationship with the efficacy of treatment (prophylaxis: regular infusion of the missing clotting factor VIII in order to prevent spontaneous bleeding) will allow for individualizing the medical behavior in a cost-effective way. For this is required to build more strong scientific evidence with statistical power that allows us to infer.
format Online
Article
Text
id pubmed-9944491
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99444912023-02-23 Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors Sarmiento Doncel, Samuel Díaz Mosquera, Gina Alejandra Cortes, Javier Mauricio Agudelo Rico, Carol Meza Cadavid, Francisco Javier Peláez, Ronald Guillermo Hematol Rep Review The purpose of this narrative review was to provide an overview that allows readers to improve their understanding of hemophilia A, which is considered a genetic disease with a high impact on the quality of life of people who suffer from it is considered one of the diseases with the highest cost for health systems (In Colombia it is part of the five diseases with the greatest economic impact). After this exhaustive review, we can see that the treatment of hemophilia is on the way to precision medicine, which involves genetic variables specific to each race and ethnicity, pharmacokinetics (PK), as well as environmental factors and lifestyle. Knowing the impact of each of these variables and their relationship with the efficacy of treatment (prophylaxis: regular infusion of the missing clotting factor VIII in order to prevent spontaneous bleeding) will allow for individualizing the medical behavior in a cost-effective way. For this is required to build more strong scientific evidence with statistical power that allows us to infer. MDPI 2023-02-16 /pmc/articles/PMC9944491/ /pubmed/36810557 http://dx.doi.org/10.3390/hematolrep15010014 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sarmiento Doncel, Samuel
Díaz Mosquera, Gina Alejandra
Cortes, Javier Mauricio
Agudelo Rico, Carol
Meza Cadavid, Francisco Javier
Peláez, Ronald Guillermo
Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors
title Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors
title_full Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors
title_fullStr Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors
title_full_unstemmed Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors
title_short Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors
title_sort haemophilia a: a review of clinical manifestations, treatment, mutations, and the development of inhibitors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944491/
https://www.ncbi.nlm.nih.gov/pubmed/36810557
http://dx.doi.org/10.3390/hematolrep15010014
work_keys_str_mv AT sarmientodoncelsamuel haemophiliaaareviewofclinicalmanifestationstreatmentmutationsandthedevelopmentofinhibitors
AT diazmosqueraginaalejandra haemophiliaaareviewofclinicalmanifestationstreatmentmutationsandthedevelopmentofinhibitors
AT cortesjaviermauricio haemophiliaaareviewofclinicalmanifestationstreatmentmutationsandthedevelopmentofinhibitors
AT agudeloricocarol haemophiliaaareviewofclinicalmanifestationstreatmentmutationsandthedevelopmentofinhibitors
AT mezacadavidfranciscojavier haemophiliaaareviewofclinicalmanifestationstreatmentmutationsandthedevelopmentofinhibitors
AT pelaezronaldguillermo haemophiliaaareviewofclinicalmanifestationstreatmentmutationsandthedevelopmentofinhibitors